GlassScriptPhysician profile
Julie Jefferson
NPI 1881915791
$5,333.33
in general payments reported to CMS, 2019-2025
30 companies · $1,141 in 2025
The $1,141 reported for 2025 was more than what 77% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,318 · 2020: $413 · 2021: $849 · 2022: $682 · 2023: $260 · 2024: $671 · 2025: $1,141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,072.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,071.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,202.72 | 2019-2025 | |
| Lilly USA, LLC | $691.03 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Janssen Biotech, INC. | $586.95 | 2020-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $393.81 | 2019-2025 | |
| Pfizer INC. | $295.70 | 2019-2022 | |
| Genzyme Corporation | $278.93 | 2019-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $249.98 | 2019-2025 | Siliq, Targretin, Duobrii |
| Leo Pharma INC. | $194.18 | 2019-2025 | Adbry |
| Medimetriks Pharmaceuticals, INC. | $174.45 | 2019-2020 | |
| Sun Pharmaceutical Industries INC. | $164.78 | 2021-2025 | Ilumya |
| Incyte Corporation | $132.96 | 2021-2025 | Opzelura |
| Ucb, INC. | $126.19 | 2025 | Bimzelx |
| Galderma Laboratories, L.P. | $102.98 | 2019-2024 | |
| Amgen INC. | $98.57 | 2020-2022 | |
| Dermira, INC. | $97.87 | 2019-2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $92.50 | 2025 | Affinity, Cygnus Dual, Simplimax |
| Regeneron Healthcare Solutions, INC. | $91.23 | 2021-2024 | Libtayo |
| Genentech USA, INC. | $63.77 | 2019-2024 | Erivedge |
| Mayne Pharma Commercial LLC | $52.93 | 2019-2022 | |
| Almirall LLC | $40.50 | 2025 | Seysara |
| Journey Medical Corporation | $34.43 | 2020-2021 | |
| Organon LLC | $28.28 | 2025 | Vtama |
| Vertex Pharmaceuticals Incorporated | $24.92 | 2024 | |
| Fresenius Kabi USA, LLC | $20.61 | 2024 | Idacio |
| Vyne Pharmaceuticals INC. | $17.60 | 2021 | |
| Paratek Pharmaceuticals, INC. | $17.52 | 2024 | Nuzyra |
| Biofrontera INC. | $17.21 | 2024 | Xepi, Bf-Rhodoled, Ameluz |
| Arcutis Biotherapeutics, INC. | $16.64 | 2024 | Zoryve |
| Bioventus LLC | $12.23 | 2022 | |
| Merck Sharp & Dohme LLC | $11.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Jefferson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.